MTOR and hepatocellular carcinoma: In summary, our study demonstrated the preclinical activity of PH, which inhibits hepatic carcinoma in vitro and in vivo and prolonged mouse survival via molecular targeting of STAT3/Akt/mTOR/JAK2/VEGF2 pathways.